Status unknownNCT01888159Updated Jun 27, 2013

Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve

An interventional study of Bilateral Salpingectomy and Tubal sterilization with bipolar energy in Ovarian Cancer, sponsored by Karlstad Central Hospital. Status unknown at 1 site in Sweden. Open to female participants aged 25 Years to 45 Years. Per ClinicalTrials.gov, last updated 2013-06-27.

Sponsored by Karlstad Central Hospital · Not applicable, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Jun 2013), so the status shown — last known as Not yet recruiting — may be out of date.

Phase: Not applicable
Study type: Interventional
Enrollment: 100
Allocation: Randomized
Ages: 25 Years to 45 Years
Sex: Female

Study summary

Randomised study to investigate if salpingectomies done to women wishing tubal sterilisation has an effect on ovarian reserve.

Conditions studied

Ovarian Cancer

Browse trials for

In context

Ovarian Neoplasms

2,695 studies on the registry are indexed under Ovarian Neoplasms; 727 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 2,030 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

Karlstad Central Hospital is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 25 Years to 45 Years
Sexes eligible: Female
Accepts healthy volunteers: No

Inclusion criteria

Women seeking for tubal sterilisation

Exclusion criteria

Exclusion Criteria:

women older than 45
family history of ovarian cancer
presence of menopausal symptoms
irregular cycles
Hormone Replacement Therapy or hormone contraceptions the last 3 months
history of previous ovarian or uterine surgeries
imaging suggesting an ovarian cyst or other adnexal pathology during investigation
previous salpingectomy

Study design

Phase: Not applicable
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel assignment
Masking: None (open label)
Enrollment: 100 participants (estimated)

Study arms

Active comparator
Tubal Sterilization with bipolar
Salpingectomy vs Tubal Sterilisation
Procedure: Tubal sterilization with bipolar energy
Active comparator
Bilateral Salpingectomy
Salpingectomy vs Tubal Sterilisation
Procedure: Bilateral Salpingectomy

Interventions

ProcedureBilateral Salpingectomy
ProcedureTubal sterilization with bipolar energy

What researchers measure

Primary outcomes

Anti-Mullerian hormone (AMH)and Follicle Stimulation Hormone (FSH)
Time frame: 3 months

Secondary outcomes

Anti-Mullerian hormone (AMH)
Time frame: 1 year
Operative time
Time frame: Postoperatively
Complications
Time frame: 3 months

Other outcomes

Follicle Stimulation Hormone (FSH)
Time frame: 3 months
Follicle Stimulation Hormone (FSH)
Time frame: 1 year

Study locations

1 site

Department of Obstetrics and Gynecology
Karlstad, Värmaland 65185, Sweden

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jun 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT01888159
Lead sponsor: Karlstad Central Hospital
Responsible party: Leonidas Magarakis (MD, Karlstad Central Hospital) — Principal investigator
First posted: Jun 27, 2013
Start date: Sep 2013
Primary completion: Sep 2014 (estimated)
Last update: Jun 27, 2013

Study contacts

Leonidas Magarakis, MD

Contact

lemagarakis@gmail.com

046737529929

Oversight

Data monitoring committee: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Ovarian Neoplasms→

Other studies from this sponsor

Karlstad Central Hospital

Start the discussion